PubRank

Robert G Uzzo

Author PubWeight™ 208.23‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Guideline for management of the clinical T1 renal mass. J Urol 2009 8.26
2 The R.E.N.A.L. nephrometry score: a comprehensive standardized system for quantitating renal tumor size, location and depth. J Urol 2009 6.71
3 Randomized trial of hypofractionated external-beam radiotherapy for prostate cancer. J Clin Oncol 2013 4.78
4 The natural history of observed enhancing renal masses: meta-analysis and review of the world literature. J Urol 2006 3.88
5 Excise, ablate or observe: the small renal mass dilemma--a meta-analysis and review. J Urol 2008 3.46
6 Evaluating overall survival and competing risks of death in patients with localized renal cell carcinoma using a comprehensive nomogram. J Clin Oncol 2009 3.38
7 Trends in radical prostatectomy: centralization, robotics, and access to urologic cancer care. Cancer 2011 3.13
8 Positron emission tomography/computed tomography identification of clear cell renal cell carcinoma: results from the REDECT trial. J Clin Oncol 2012 3.03
9 Cutaneous metastases from genitourinary malignancies. Urology 2004 2.97
10 Objective measures of renal mass anatomic complexity predict rates of major complications following partial nephrectomy. Eur Urol 2011 2.87
11 Cryoablation or radiofrequency ablation of the small renal mass : a meta-analysis. Cancer 2008 2.75
12 Comparison of cold and warm ischemia during partial nephrectomy in 660 solitary kidneys reveals predominant role of nonmodifiable factors in determining ultimate renal function. J Urol 2010 2.53
13 Academic ranking score: a publication-based reproducible metric of thought leadership in urology. Eur Urol 2011 2.51
14 Anatomic features of enhancing renal masses predict malignant and high-grade pathology: a preoperative nomogram using the RENAL Nephrometry score. Eur Urol 2011 2.22
15 Prevalence of baseline chronic kidney disease in patients presenting with solid renal tumors. Urology 2011 2.20
16 Dosimetry and preliminary acute toxicity in the first 100 men treated for prostate cancer on a randomized hypofractionation dose escalation trial. Int J Radiat Oncol Biol Phys 2005 2.08
17 Promoter hypermethylation profile of kidney cancer. Clin Cancer Res 2004 2.02
18 Small renal masses progressing to metastases under active surveillance: a systematic review and pooled analysis. Cancer 2011 1.98
19 The Phoenix definition of biochemical failure predicts for overall survival in patients with prostate cancer. Cancer 2008 1.98
20 Rationale for percutaneous biopsy and histologic characterisation of renal tumours. Eur Urol 2012 1.95
21 Urinary cytology has a poor performance for predicting invasive or high-grade upper-tract urothelial carcinoma. BJU Int 2011 1.78
22 Lymphopenia is an independent predictor of inferior outcome in clear cell renal carcinoma. J Urol 2012 1.78
23 Baseline renal function status limits patient eligibility to receive perioperative chemotherapy for invasive bladder cancer and is minimally affected by radical cystectomy. Urology 2010 1.77
24 The expanding role of partial nephrectomy: a critical analysis of indications, results, and complications. Eur Urol 2009 1.70
25 Delayed intervention of sporadic renal masses undergoing active surveillance. Cancer 2008 1.64
26 Trends in regionalization of adrenalectomy to higher volume surgical centers. J Urol 2012 1.64
27 Natural history, growth kinetics, and outcomes of untreated clinically localized renal tumors under active surveillance. Cancer 2009 1.60
28 Enhancing renal masses with zero net growth during active surveillance. J Urol 2007 1.59
29 Role of prostate dose escalation in patients with greater than 15% risk of pelvic lymph node involvement. Int J Radiat Oncol Biol Phys 2005 1.57
30 Assessing performance trends in laparoscopic nephrectomy and nephron-sparing surgery for localized renal tumors. Urology 2012 1.54
31 Identification of novel target genes by an epigenetic reactivation screen of renal cancer. Cancer Res 2006 1.49
32 Clinical characteristics associated with treatment type for localized renal tumors: implications for practice pattern assessment. Urology 2013 1.49
33 Decision-making strategies for patients with localized prostate cancer. Semin Urol Oncol 2002 1.48
34 Nephron-sparing management vs radical nephroureterectomy for low- or moderate-grade, low-stage upper tract urothelial carcinoma. BJU Int 2014 1.47
35 Utility of the R.E.N.A.L. nephrometry scoring system in objectifying treatment decision-making of the enhancing renal mass. Urology 2011 1.46
36 Role of tumor location in selecting patients for percutaneous versus surgical cryoablation of renal masses. Can J Urol 2012 1.45
37 Robot-assisted partial nephrectomy: a large single-institutional experience. Urology 2010 1.45
38 Preoperative hydronephrosis, ureteroscopic biopsy grade and urinary cytology can improve prediction of advanced upper tract urothelial carcinoma. J Urol 2010 1.44
39 Comparison of prostate cancer diagnosis in patients receiving unrelated urological and non-urological cancer care. BJU Int 2013 1.41
40 Why Summary Comorbidity Measures Such As the Charlson Comorbidity Index and Elixhauser Score Work. Med Care 2015 1.41
41 Enhancing renal tumors in patients with prior normal abdominal imaging: further insight into the natural history of renal cell carcinoma. J Urol 2012 1.40
42 The need for androgen deprivation therapy in patients with intermediate-risk prostate cancer treated with dose-escalated external beam radiation therapy. Can J Urol 2017 1.39
43 The relationship of increasing radiotherapy dose to reduced distant metastases and mortality in men with prostate cancer. Cancer 2004 1.38
44 How Hugh Hampton Young's treatment of President Woodrow Wilson's urinary retention and urosepsis affected the resolution of World War I. J Urol 2011 1.38
45 Histopathological characteristics of localized renal cell carcinoma correlate with tumor size: a SEER analysis. J Urol 2008 1.37
46 Race, genetic West African ancestry, and prostate cancer prediction by prostate-specific antigen in prospectively screened high-risk men. Cancer Prev Res (Phila) 2009 1.36
47 Clinicopathological outcomes after radical cystectomy for clinical T2 urothelial carcinoma: further evidence to support the use of neoadjuvant chemotherapy. BJU Int 2011 1.31
48 Prostate cancer risk assessment program: a 10-year update of cancer detection. J Urol 2007 1.28
49 Prostate cancer radiotherapy dose response: an update of the fox chase experience. J Urol 2004 1.26
50 Residual and recurrent disease following renal energy ablative therapy: a multi-institutional study. J Urol 2006 1.23
51 Detection of bladder cancer in urine by a tumor suppressor gene hypermethylation panel. Clin Cancer Res 2004 1.22
52 Contemporary management of small renal masses. Eur Urol 2011 1.19
53 Timing of biochemical failure and distant metastatic disease for low-, intermediate-, and high-risk prostate cancer after radiotherapy. Cancer 2007 1.18
54 A review of contemporary data on surgically resected renal masses--benign or malignant? Urology 2013 1.15
55 Promoter hypermethylation of tumor suppressor genes in urine from kidney cancer patients. Cancer Res 2003 1.13
56 Overexpression of the zinc uptake transporter hZIP1 inhibits nuclear factor-kappaB and reduces the malignant potential of prostate cancer cells in vitro and in vivo. Clin Cancer Res 2008 1.12
57 Predicting growth of solid renal masses under active surveillance. Urol Oncol 2008 1.11
58 Treatment of patients with metastatic renal cell cancer: a RAND Appropriateness Panel. Cancer 2006 1.10
59 Modulation of Akt/mTOR signaling overcomes sunitinib resistance in renal and prostate cancer cells. Mol Cancer Ther 2012 1.09
60 Radiation therapy dose escalation for prostate cancer: a rationale for IMRT. World J Urol 2003 1.06
61 PD-1 expression on peripheral blood cells increases with stage in renal cell carcinoma patients and is rapidly reduced after surgical tumor resection. Cancer Immunol Res 2013 1.06
62 Optimal management of localized renal cell carcinoma: surgery, ablation, or active surveillance. J Natl Compr Canc Netw 2009 1.05
63 Age, tumor size and relative survival of patients with localized renal cell carcinoma: a surveillance, epidemiology and end results analysis. J Urol 2008 1.05
64 Tumor size predicts synchronous metastatic renal cell carcinoma: implications for surveillance of small renal masses. J Urol 2007 1.05
65 Use of systemic therapy and factors affecting survival for patients undergoing cytoreductive nephrectomy. BJU Int 2009 1.05
66 Incidence and management of penetrating renal trauma in patients with multiorgan injury: extended experience at an inner city trauma center. J Urol 2004 1.04
67 Serum amino acid levels as a biomarker for renal cell carcinoma. J Urol 2011 1.02
68 Low rates of adjuvant radiation in patients with nonmetastatic prostate cancer with high-risk pathologic features. Cancer 2014 1.02
69 Radiation dose and late failures in prostate cancer. Int J Radiat Oncol Biol Phys 2006 1.01
70 Competing risks of death in patients with localized renal cell carcinoma: a comorbidity based model. J Urol 2012 1.01
71 Perioperative outcomes of robotic and open partial nephrectomy for moderately and highly complex renal lesions. J Urol 2012 1.01
72 Long-term androgen deprivation increases Grade 2 and higher late morbidity in prostate cancer patients treated with three-dimensional conformal radiation therapy. Int J Radiat Oncol Biol Phys 2005 1.00
73 Piperlongumine induces rapid depletion of the androgen receptor in human prostate cancer cells. Prostate 2012 1.00
74 Evaluation and management of the renal mass. Med Clin North Am 2011 0.99
75 Piperlongumine inhibits NF-κB activity and attenuates aggressive growth characteristics of prostate cancer cells. Prostate 2013 0.99
76 Does a delay in external beam radiation therapy after tissue diagnosis affect outcome for men with prostate carcinoma? Cancer 2005 0.97
77 Active surveillance: a potential strategy for select patients with small renal masses. Future Oncol 2011 0.97
78 Defining biochemical failure after radiotherapy with and without androgen deprivation for prostate cancer. Int J Radiat Oncol Biol Phys 2005 0.96
79 Renal masses herniating into the hilum: technical considerations of the "ball-valve phenomenon" during nephron-sparing surgery. Urology 2009 0.96
80 Vitamin E succinate inhibits NF-kappaB and prevents the development of a metastatic phenotype in prostate cancer cells: implications for chemoprevention. Prostate 2007 0.96
81 Does partial nephrectomy result in a durable overall survival benefit in the Medicare population? J Urol 2012 0.96
82 Elevated expression of stromal palladin predicts poor clinical outcome in renal cell carcinoma. PLoS One 2011 0.95
83 Association of tumor size with metastatic potential and survival in patients with adrenocortical carcinoma: an analysis of the National Cancer Database. Can J Urol 2013 0.95
84 Methylseleninic acid sensitizes prostate cancer cells to TRAIL-mediated apoptosis. Oncogene 2005 0.95
85 Transcriptional regulation of the major zinc uptake protein hZip1 in prostate cancer cells. Gene 2008 0.95
86 Partial nephrectomy for renal masses ≥ 7 cm: technical, oncological and functional outcomes. BJU Int 2012 0.94
87 The rise and fall of prostate brachytherapy: use of brachytherapy for the treatment of localized prostate cancer in the National Cancer Data Base. Cancer 2014 0.94
88 Differential use of partial nephrectomy for intermediate and high complexity tumors may explain variability in reported utilization rates. J Urol 2013 0.94
89 Biochemical failure and the temporal kinetics of prostate-specific antigen after radiation therapy with androgen deprivation. Int J Radiat Oncol Biol Phys 2005 0.94
90 The genetics of renal oncocytosis: a possible model for neoplastic progression. Cancer Genet Cytogenet 2004 0.93
91 Targeted therapies for kidney cancer in urologic practice. Urol Oncol 2007 0.93
92 Should partial nephrectomy be offered to all patients whenever technically feasible? Eur Urol 2011 0.92
93 Effects of increased cross-sectional imaging on the diagnosis and prognosis of adrenocortical carcinoma: analysis of the National Cancer Database. J Urol 2011 0.92
94 Validation of a treatment policy for patients with prostate specific antigen failure after three-dimensional conformal prostate radiation therapy. Cancer 2003 0.92
95 The proportion of prostate biopsy tissue with Gleason pattern 4 or 5 predicts for biochemical and clinical outcome after radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys 2007 0.91
96 High-grade ureteroscopic biopsy is associated with advanced pathology of upper-tract urothelial carcinoma tumors at definitive surgical resection. J Endourol 2012 0.91
97 Depletion of intracellular zinc increases expression of tumorigenic cytokines VEGF, IL-6 and IL-8 in prostate cancer cells via NF-kappaB-dependent pathway. Prostate 2008 0.91
98 Adjuvant and neoadjuvant therapy for renal cell carcinoma: a survey of the Society of Urologic Oncology. Urol Oncol 2012 0.91
99 Routine adrenalectomy is unnecessary during surgery for large and/or upper pole renal tumors when the adrenal gland is radiographically normal. J Urol 2011 0.91
100 Pathologic concordance of sporadic synchronous bilateral renal masses. Urology 2008 0.90
101 Pathological concordance and surgical outcomes of sporadic synchronous unilateral multifocal renal masses treated with partial nephrectomy. J Urol 2012 0.89
102 Trends in regionalization of radical cystectomy in three large northeastern states from 1996 to 2009. Urol Oncol 2012 0.88
103 Adjuvant therapy for high-risk renal cell carcinoma patients. Curr Urol Rep 2007 0.87
104 Metanephric adenofibroma: robotic partial nephrectomy of a large Wilms' tumor variant. Can J Urol 2010 0.87
105 Prior abdominal surgery and radiation do not complicate the retroperitoneoscopic approach to the kidney or adrenal gland. J Urol 2005 0.86
106 Interleukin-6: a potential biomarker of resistance to multitargeted receptor tyrosine kinase inhibitors in castration-resistant prostate cancer. Urology 2011 0.86
107 Intensity-modulated radiotherapy with MRI simulation to reduce doses received by erectile tissue during prostate cancer treatment. Int J Radiat Oncol Biol Phys 2004 0.86
108 Active surveillance of small renal masses. Nat Rev Urol 2013 0.86
109 Is radical nephrectomy a legitimate therapeutic option in patients with renal masses amenable to nephron-sparing surgery? BJU Int 2014 0.86
110 Multi-institutional validation of the ability of preoperative hydronephrosis to predict advanced pathologic tumor stage in upper-tract urothelial carcinoma. Urol Oncol 2011 0.86
111 Evaluation of the Prostate Cancer Prevention Trial Risk calculator in a high-risk screening population. BJU Int 2009 0.85
112 Combined classical cytogenetics and microarray-based genomic copy number analysis reveal frequent 3;5 rearrangements in clear cell renal cell carcinoma. Genes Chromosomes Cancer 2010 0.85
113 The natural history of untreated renal masses. BJU Int 2007 0.85
114 Percutaneous vs surgical cryoablation of the small renal mass: is efficacy compromised? BJU Int 2010 0.85
115 Familiarity and self-reported compliance with American Urological Association best practice recommendations for use of thromboembolic prophylaxis among American Urological Association members. J Urol 2013 0.84
116 Reversal of epigenetic silencing of AP-2alpha results in increased zinc uptake in DU-145 and LNCaP prostate cancer cells. Carcinogenesis 2011 0.84
117 Assessing the clinical role of genetic markers of early-onset prostate cancer among high-risk men enrolled in prostate cancer early detection. Cancer Epidemiol Biomarkers Prev 2011 0.84
118 Variation in performance of candidate surgical quality measures for muscle-invasive bladder cancer by hospital type. BJU Int 2014 0.84
119 Docetaxel-mediated apoptosis in myeloid progenitor TF-1 cells is mitigated by zinc: potential implication for prostate cancer therapy. Prostate 2011 0.83
120 Tyrosine kinase inhibitors and anti-angiogenic therapies in kidney cancer. Curr Treat Options Oncol 2007 0.83
121 Renal masses--to treat or not to treat? If that is the question are contemporary biomarkers the answer? J Urol 2008 0.83
122 The radiation doses to erectile tissues defined with magnetic resonance imaging after intensity-modulated radiation therapy or iodine-125 brachytherapy. Int J Radiat Oncol Biol Phys 2004 0.83
123 Are all multi-targeted tyrosine kinase inhibitors created equal? An in vitro study of sunitinib and pazopanib in renal cell carcinoma cell lines. Can J Urol 2011 0.83
124 Co-administration of piperine and docetaxel results in improved anti-tumor efficacy via inhibition of CYP3A4 activity. Prostate 2011 0.83
125 Clinical Stage T1 micropapillary urothelial carcinoma presenting with metastasis to the pancreas. Urology 2011 0.82
126 Does short-term androgen deprivation substitute for radiation dose in the treatment of high-risk prostate cancer? Int J Radiat Oncol Biol Phys 2003 0.82
127 Cadmium down-regulates expression of XIAP at the post-transcriptional level in prostate cancer cells through an NF-kappaB-independent, proteasome-mediated mechanism. Mol Cancer 2010 0.81
128 PSA Doubling Time Predicts for the Development of Distant Metastases for Patients Who Fail 3DCRT Or IMRT Using the Phoenix Definition. Pract Radiat Oncol 2011 0.81
129 Adjuvant and neoadjuvant therapies in high-risk renal cell carcinoma. Hematol Oncol Clin North Am 2011 0.81
130 Balancing process and risk: standardizing posttreatment surveillance for renal cell carcinoma. J Urol 2013 0.80
131 Genome-wide promoter methylome of small renal masses. PLoS One 2013 0.80
132 RENAL nephrometry scoring system: the radiologist's perspective. AJR Am J Roentgenol 2012 0.80
133 An intraoperative real-time sleeved seed technique for permanent prostate brachytherapy. Brachytherapy 2009 0.80
134 Partial versus radical nephrectomy: balancing nephrons and perioperative risk. Eur Urol 2013 0.79
135 How can men destined for biochemical failure after androgen deprivation and radiotherapy be identified earlier? Int J Radiat Oncol Biol Phys 2007 0.79
136 Impact of target volume coverage with Radiation Therapy Oncology Group (RTOG) 98-05 guidelines for transrectal ultrasound guided permanent Iodine-125 prostate implants. Radiother Oncol 2003 0.79
137 Focal therapy for kidney cancer: a systematic review. Curr Opin Urol 2009 0.79
138 Modifying the American Society for Therapeutic Radiology and Oncology definition of biochemical failure to minimize the influence of backdating in patients with prostate cancer treated with 3-dimensional conformal radiation therapy alone. J Urol 2003 0.79
139 Shared decision-making strategies for early prostate cancer. Semin Urol Oncol 2002 0.79
140 Delayed proximal ureteric stricture formation after complex partial nephrectomy. BJU Int 2011 0.78
141 Adrenocortical carcinoma masquerading as a benign adenoma on computed tomography washout study. Urology 2011 0.78
142 The effect of 5-aminolevulinic acid and its derivatives on protoporphyrin IX accumulation and apoptotic cell death in castrate-resistant prostate cancer cells. Urology 2012 0.78
143 Piperlongumine and its analogs down-regulate expression of c-Met in renal cell carcinoma. Cancer Biol Ther 2015 0.78
144 The evolving management of small renal masses. Curr Oncol Rep 2009 0.78
145 Gleason scoring at a comprehensive cancer center: what's the difference? J Natl Compr Canc Netw 2013 0.78
146 Young age under 60 years is not a contraindication to treatment with definitive dose escalated radiotherapy for prostate cancer. Radiother Oncol 2011 0.77
147 A prostate specific antigen (PSA) bounce greater than 1.4 ng/mL Is clinically significant after external beam radiotherapy for prostate cancer. Am J Clin Oncol 2006 0.77
148 What pretreatment prostate-specific antigen level warrants long-term androgen deprivation? Int J Radiat Oncol Biol Phys 2005 0.77
149 Coupling of prostate and thyroid cancer diagnoses in the United States. Ann Surg Oncol 2014 0.77
150 Is there a benefit to frozen section analysis at the time of partial nephrectomy? Can J Urol 2013 0.77
151 Small renal mass. N Engl J Med 2010 0.77
152 Positive prostate biopsy laterality and implications for staging. Urology 2003 0.77
153 Kidney cancer in 2011: objectifying risk for localized renal masses. Nat Rev Urol 2011 0.77
154 Understanding Treatment Disconnect and Mortality Trends in Renal Cell Carcinoma Using Tumor Registry Data. Med Care 2016 0.76
155 Use of radical cystectomy as initial therapy for the treatment of high-grade T1 urothelial carcinoma of the bladder: a SEER database analysis. Urol Oncol 2011 0.76
156 Treatment of the 2 to 3 cm renal mass. J Urol 2010 0.76
157 Thermal ablation of the small renal mass: case selection using the R.E.N.A.L.-Nephrometry Score. Urol Oncol 2012 0.76
158 Molecular imaging of the small renal mass. Urol Oncol 2011 0.76
159 Management of small renal masses. Semin Ultrasound CT MR 2009 0.76
160 Thinking beyond surgery in the management of renal cell carcinoma: the risk to die from renal cell carcinoma and competing risks of death. World J Urol 2014 0.76
161 Editorial comment. J Urol 2009 0.75
162 Renal cell carcinoma: urologists in a new era. J Urol 2005 0.75
163 Androgen suppression plus radiation therapy for prostate cancer. JAMA 2004 0.75
164 Re: improved clinical staging system combining biopsy laterality and TNM stage for men with T1c and T2 prostate cancer: results from the search database. J Urol 2004 0.75
165 Racial differences in prediction of time to prostate cancer diagnosis in a prospective screening cohort of high-risk men: effect of TMPRSS2 Met160Val. BJU Int 2010 0.75
166 Residual prostate cancer after radiotherapy: a study of radical cystoprostatectomy specimens. Urology 2008 0.75
167 The Kubler-Ross model, physician distress, and performance reporting. Nat Rev Urol 2013 0.75
168 Editorial comment. Urology 2009 0.75
169 Familial clustering of sporadic kidney cancer: insufficient evidence to recommend routine screening in unaffected kin. Eur Urol 2011 0.75
170 Meaningful comparison of robotics versus laparoscopy for nephron-sparing surgery: no contest or no dice? Eur Urol 2012 0.75
171 The burden of overtreatment: comparison of toxicity between single and combined modality radiation therapy among low risk prostate cancer patients. Can J Urol 2015 0.75
172 The role of minimally invasive surgery in multifocal renal cell carcinoma. Curr Urol Rep 2012 0.75
173 Brachytherapy for prostate cancer: follow-up and management of treatment failures. Urol Clin North Am 2003 0.75
174 Current status of robot-assisted partial nephrectomy. Curr Urol Rep 2012 0.75
175 Matched-cohort analysis of patients with prostate cancer followed with observation or treated with three-dimensional conformal radiation therapy. BJU Int 2004 0.75
176 Prostate cancer and the educated consumer. Semin Urol Oncol 2002 0.75
177 Patient reported outcomes among treatment modalities for prostate cancer. Can J Urol 2016 0.75
178 Intensely positron emission tomography-avid benign adrenal adenoma. Urology 2011 0.75
179 Fourth joint meeting of the American Urological Association and the Japanese Urological Association Specialty Society program at the 104th annual meeting of the American Urological Association at Chicago 2009. Int J Urol 2009 0.75
180 How Chester Alan Arthur 'brightened' from a political spoilsman to a civil service reformer. BJU Int 2011 0.75
181 Prolonged natural progression from localized to symptomatic renal cell carcinoma. Can J Urol 2012 0.75
182 Andrew Johnson's rocky medical and political 'calculous'. BJU Int 2010 0.75